58: Acute Quality of Life Changes after Stereotactic Ablative Radiotherapy for Liver Metastasis: A Prospective Cohort Analysis
Abstract Purpose To report the changes in quality of life (QoL) after stereotactic ablative radiotherapy (SABR) in patients with liver metastases (LM) Materials and methods A prospective cohort study was undertaken to measure the acute changes in QoL after SABR. Patients with 1 3 treated LM were eligible. Doses of 30 60 Gy in 3 5 fractions were delivered. Prospective QoL was measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires, Core 15 for Palliative Care (EORTC QLQ C15 PAL) and liver metastases (LM21) at baseline, 1st week and last day of treatment, then 1, 6 and 12 weeks after SABR. The functional living index emesis (FLIE) was collected at baseline, 1st week, last day and 1 week after treatment. Univariable and multivariable linear mixed modeling were performed as appropriate to assess changes in QoL over time. Results Sixty patients were included. The most common primary cancer was colorectal (42% The global health score measured by QLQ C15 PAL was significantly worse at treatment completion (p 0.001) 1 week (p 0.003) and 6 weeks (p 0.002) after SABR but recovered by 12 weeks (p 0.124) Nausea and constipation were worse at treatment completion (p Conclusion SABR offers a non invasive mean of ablating LM with minimal impact on acute QoL.